Erin Bastick, PharmD, RPh
Cannabinoid-based drug pipeline shows promise
Cannabinoid-based drug pipeline shows promise
New treatment indications are under investigation for the use of cannabinoid-based drugs.
Cannabinoid-based drug pipeline grows: 4 ways to prepare
New treatment indications are under investigation for the use of cannabinoid-based drugs. Are you ready?
New diabetes medications help address linked diseases
Experts share updates on new diabetes medications, and provide an overview of what’s coming.
Four things health execs should know about the oncology pipeline
Four things health execs should know about the oncology pipeline
Here’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care.
Statin prescribing varies in patients with diabetes
Wide variation exists in practice-level statin prescribing for patients with diabetes, according to a new study.
Insurer diabetes program engages consumers, lowers costs
Insurer diabetes program engages consumers, lowers costs
Anthem Blue Cross recently launched a year-long diabetes prevention program to educate, treat and support its qualified California members who are at risk of developing type 2 diabetes.
Drug pipeline developments: Alopecia areata and atopic dermatitis
Promising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.
Know these barriers to reduce type 2 diabetes costs
IMS Health study: Up to 15% of healthcare system costs avoidable and effective patient activation by multiple stakeholders is key to driving improvement.
Aggressive blood sugar control slows diabetic eye disease progression
NIH-funded study shows less diabetic retinopathy progression among those who underwent intensive glycemic control.
Patient navigators can benefit diabetes outcomes
Study seeks to determine whether significant improvement in glycemic control can be achieved when regular coaching is part of the process.

Poll

View Results